Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Healthcare Biotechnology
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Post by dollarhunteron May 28, 2004 7:02pm
130 Views
Post# 7545925

News... A very good sign.

News... A very good sign.Regards, DH Adherex Technologies Inc. Quick Quote: AHX 0.57 (+0.06) OrbiMed Advisors, LLC: Press Release 5/28/04 NEW YORK, NEW YORK, May 28, 2004 (CCNMatthews via COMTEX) -- CANADA ONLY Pursuant to a private placement on May 20, 2004, OrbiMed, acting on behalf of various of its investment advisory clients, acquired from Adherex Technologies Inc. beneficial ownership of 3,773,585 common shares and 1,886,792 warrants c onvertible into common shares which, together with its holdings of 11,450,000 common shares and 5,725,000 warrants convertible into common shares, represents aggregate ownership of approximately 13.01% of the total outstanding common shares of Adherex. OrbiMed invests in the biotechnology and pharmaceutical sectors and may increase or decrease its holdings in Adherex depending on market conditions and other relevant factors. OrbiMed Advisors, LLC Eric Bittelman (212) 739-6400 bittelmane@orbimed.com 767 Third Avenue, 30th Floor, New York, NY 10017 NEWS RELEASE TRANSMITTED BY CCNMatthews Copyright (C) 2004, CCNMatthews. All rights reserved.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities